	US 12,188,095 B2
	Methods and compositions for identifying and treating patients with small cell lung cancer
Trudy Oliver, Salt Lake City, UT (US); Martin Sos, Salt Lake City, UT (US); and Robert Wechsler-Reya, Salt Lake City, UT (US)
Assigned to UNIVERSITY OF UTAH RESEARCH FOUNDATION, Salt Lake City, UT (US)
Filed by UNIVERSITY OF UTAH RESEARCH FOUNDATION, Salt Lake City, UT (US)
Filed on Sep. 20, 2021, as Appl. No. 17/479,701.
Application 17/479,701 is a continuation of application No. 16/335,368, granted, now 11,124,841, previously published as PCT/US2017/058782, filed on Oct. 27, 2017.
Claims priority of provisional application 62/444,968, filed on Jan. 11, 2017.
Claims priority of provisional application 62/414,362, filed on Oct. 28, 2016.
Prior Publication US 2022/0073998 A1, Mar. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6886 (2018.01)

CPC C12Q 1/6886 (2013.01) [C12Q 2600/106 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/158 (2013.01)]

2 Claims

1. A method of predicting the success of an aurora kinase inhibitor or a BCL-2 inhibitor in a patient with small cell lung cancer and treating the patient, the method comprising:

a. obtaining a sample from the patient;

b. determining the level of (i) NEUROD1, (ii) Myc or Mycl, and (iii) ASCL1 in the patient's sample;

c. comparing the levels of (i) NEUROD1, (ii) Myc or Mycl and (iii) ASCL1 of the patient's sample to a sample from a human subject that does not have small cell lung cancer, and

d. determining that the patient will successfully respond to an aurora kinase inhibitor when an increased level of NEUROD1, an increased level of Myc or a decreased level of Myc1, and a decreased level of ASCL1 is determined from the patient's sample, and subsequently administering to the patient the aurora kinase inhibitor, or

determining that the patient will successfully respond to a BCL-2 inhibitor when a decreased level of NEUROD1, an increased level of Myc1 or a decreased level of Myc, and an increased level of ASCL1 is determined from the patient's sample, and subsequently administering to the patient the BCL-2 inhibitor.